{
    "2020-08-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Early Sales of Eli Lilly's Migraine Drug Disappoint",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Migraine Drug",
                        "Disappoint"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-22",
                "original_text": "FDA Approves Glaxoâ€™s First Homegrown Cancer Drug Since It Sold Cancer Pipeline",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approves",
                        "Glaxo",
                        "Cancer Drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO",
                "features": {
                    "keywords": [
                        "FDA",
                        "Nod",
                        "GlaxoSmithKline",
                        "Bristol-Myers Squibb",
                        "Earnings",
                        "Acutus Medical IPO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}